Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth

Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 1

Abstract

Objective — to study the effects of three-month administration of the combined cytoprotector L-Betargin on the lipid and carbohydrate metabolism, biochemical markers of liver damage, the degree of its steatosis and fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) against the background of metabolic syndrome (MS), depending on the presence of syndrome of intestinal bacterial overgrowth (SIBO) and after its correction with probiotic Spazmolac. Materials and methods. Observations involved 60 patients with NASH, developing against the MS background. The diagnosis of steatohepatitis was established based on the multimodal sonographic study of the liver, including conventional echography, Doppler sonography, shear wave elastography, and liver steatometry. The degree of steatosis (S1-S3) was determined by the attenuation coefficient (CG) of the ultrasonic wave SAR, the degree of fibrosis (F1-F4) by the average hardness of the parenchyma. The MS presence was confirmed with generally accepted diagnostic criteria. The SIBO diagnosis was established using the H2-lactulose hydrogen test. All patients were evaluated abdominal symptoms — dyspepsia, pain, bloating, stool frequency. The biochemistry included determination of the transaminases, gamma-glutamine transferase, the levels of bilirubin and fractions, HbA1c, cholesterol, low and high-density lipoproteins, triglycerides. The patients were randomized into two comparable groups. The first group consisted of 30 subjects, who were administered L-Betargin for 3 months in a dose of 1 stick 3 times a day, 30 patients of second group people took silymarin 45 mg 3 times a day. Four weeks after the treatment start, the SIBR, biochemical parameters and multimodal liver sonography were monitored with an assessment of the steatosis and fibrosis degree. In case of SIBR presence, the probiotic Spazmolac, 1 capsule per day for 4 weeks, was added to the treatment. In 12 weeks after the treatment start, clinical, biochemical, sonographic indicators and SIBR were re-evaluated. Results. The use of L-Betargin in NAFLD for 12 weeks in a dose of 1 stick 3 times a day resulted in the significant suppression of cytolysis, a decrease in liver steatosis, an improvement in lipid metabolism and portal blood flow rates, and also reduction of the risk of developing or progression of atherosclerosis, cardiovascular diseases and insulin resistance. Conclusions. Due to its combined composition, synergy of mechanisms of action and normalization of metabolic disorders, L-Betargin contributes to the elimination of asthenic syndrome in patients with NAFLD and improves their quality of life. The four-week administration of the probiotic Spazmolac promoted almost two-fold SIBO reduction, that was accompanied by a significant decrease in the severity of abdominal pain, bloating and diarrhea. The use of L-Betargin resulted in the increased efficacy of SIBR eradication.

Authors and Affiliations

A. E. Dorofeyev, M. M. Rudenko, S. M. Tkach, Yu. Z. Dynia

Keywords

Related Articles

A clinical case of eosinophilic esophagitis combined with macroamylasemia

Eosinophilic esophagitis is one of the most prevalent esophageal diseases and the leading cause of dysphagia and food impaction in children and young adults. The authors presented a clinical case of a patient with eosino...

The role of serum biomarkers in the diagnosis of nonalcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by liver steatosis and the ability to progress to more serious pathological conditions, including non-alcoholic steatohepatitis (NASH), fibrosis and ci...

Irritable bowel syndrome at young age: Salofalk treatment efficacy

Objective — to analyze the effect of granules of mesalazine on the course of IBS in adolescents and young patients. Materials and methods. We observed 58 children in late adolescence from 15 to 18 years old and 120 youn...

The rational choice of drugs for the dyspepsia treatment in an outpatient clinic

Objective — to conduct a comparative evaluation of the clinical efficacy of pantoprazole, aluminium phosphate gel and drotaverine in the treatment of patients with dyspepsia. Materials and methods. The open comparative...

Helicobacter pylori infection and acid-related diseases against the background of metabolic-associated conditions: mechanisms of development and management

The author presents data on the role of H. pylori infection in the initiation and progression of the changes in metabolic status of patients with type 2 diabetes mellitus (DM-2), insulin resistance, obesity, cardiovascul...

Download PDF file
  • EP ID EP508547
  • DOI 10.30978/MG-2019-1-77
  • Views 244
  • Downloads 0

How To Cite

A. E. Dorofeyev, M. M. Rudenko, S. M. Tkach, Yu. Z. Dynia (2019). Complex therapy of non-alcoholic fatty liver disease in combination with the syndrome of intestinal bacterial overgrowth. Сучасна гастроентерологія, 0(1), 77-84. https://europub.co.uk/articles/-A-508547